A Retrospective Study Evaluating Efficacy and Safety Of Erythropoietic-Stimulating Agents (ESA) With Ruxolitinib In Patients With Myelofibrosis.
Phase of Trial: Phase IV
Latest Information Update: 21 Jan 2017
At a glance
- Drugs Darbepoetin alfa (Primary) ; Epoetin alfa (Primary) ; Epoetin beta (Primary) ; Epoetin theta (Primary) ; Epoetin zeta (Primary) ; Ruxolitinib (Primary)
- Indications Anaemia; Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2017 New trial record
- 06 Dec 2016 Results (analysis date July 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.